Abstract

Purpose: To assess the safety of prophylactic intracameral Moxifloxacin 0.5% Ophthalmic solution in preventing Post cataract extraction endophthalmitis. Material and methods: The study was conducted at Vijayanagar Institute of Medical Sciences, Bellary, from February 2010 to April 2011. Preoperative and 1-month postoperative anterior chamber reaction was assessed in 50 eyes that had cataract surgery with intracameral moxifloxacin. All patients received 0.1 mL intracameral Moxifloxacin 0.5% ophthalmic solution containing 500 mg of Moxifloxacin at the end of surgery. Patients were assessed for following one month post operatively. Results: 50 eyes completed the study. The mean age was 56 years (range 40 to 70 years). All eyes had quiet anterior chamber preoperatively, later trace to +2 cells and flare anterior chamber reaction on the first day post surgery. Post operative evaluation was done on day 1, one week later and one month later. There was no signs of anterior chamber reaction, decrease in endothelial cell count and changes in corneal thickness was not very significant. Conclusion: Intracameral moxifloxacin 0.5mg/mL appeared to be safe in preventing postoperative anterior chamber reaction with no significant adverse effect on number of endothelial cells, corneal thickness in patients who have undergone extra capsular cataract extraction surgery